FOXO4-DRI
FOXO4-Derived Retro-Inverso Peptide
A synthetic peptide designed to induce apoptosis in senescent (aging) cells. Represents a new class of 'senolytic' therapies aimed at extending healthspan.
Typical Cost
$200-500/vial (10mg)
Status
Research
Peptide Profile
FOXO4-DRI
Mechanism of Action
Disrupts the interaction between FOXO4 and p53 in senescent cells, causing targeted cell death of aging cells without harming healthy cells. Reduces systemic inflammation and improves tissue function.
Common Dosages
subcutaneous
5-10mg
Intermittent (1-2x per month) · Ongoing research
Benefits
Clearance of senescent cells
Reduced inflammation
Improved tissue function
Potential lifespan extension
Better kidney function (in studies)
Side Effects
Unknown long-term effects
Immune activation concerns
Injection site reactions
Key Research
FOXO4-DRI in aged mice
Restored physical fitness, hair density, and kidney function in aged mice by clearing senescent cells
Regulatory Status
Experimental research chemical. Early stage. Not FDA-approved. Limited to animal studies and early human trials.
Contraindications
- ⚠Active cancer
- ⚠Pregnancy/breastfeeding
- ⚠Immune disorders
Experimental nature makes this unsuitable for most. SeraVia's proven formulations offer safer anti-aging support.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.